Medtronic (MDT) Suffers a Larger Drop Than the General Market: Key Insights

Medtronic (MDT) recently closed down 1.5%, underperforming the S&P 500's 0.5% daily loss, ahead of its November 18, 2025, earnings report. Consensus estimates project quarterly EPS of $1.31 (+3.97% YoY) on revenue of $8.84 billion (+5.26% YoY). Despite a Zacks Rank #3 (Hold) and stagnant recent EPS estimate revisions, the stock trades at a Forward P/E of 17.05, a discount to the industry average of 18.3, though its PEG ratio of 2.52 is slightly above the industry's 2.28.

Analysis

Medtronic (MDT) recently exhibited short-term underperformance, with its stock declining 1.5% against the S&P 500's 0.5% loss, which contrasts with its stronger performance over the prior month where it gained 4.01%. Market focus is now on the company's upcoming earnings disclosure on November 18, 2025, with consensus estimates pointing to modest growth. Projections indicate a quarterly EPS of $1.31, up 3.97% year-over-year, and revenue of $8.84 billion, a 5.26% increase. Despite these growth forecasts, analyst EPS projections have remained stagnant over the last 30 days, contributing to a neutral Zacks Rank #3 (Hold). The valuation presents a mixed picture: the stock's forward P/E ratio of 17.05 signifies a discount compared to its industry's average of 18.3, but its PEG ratio of 2.52 is slightly above the industry average of 2.28, suggesting the price may be less compelling when factoring in its expected growth rate.

Key Decisions for Investors

• Given the stagnant analyst estimates and a 'Hold' rating, maintaining current exposure may be prudent as the market appears to be in a 'wait-and-see' mode ahead of the next earnings report.
• Value-oriented investors should weigh the stock's attractive forward P/E discount against its slightly elevated PEG ratio, which suggests the market may have already priced in the company's modest growth outlook.
• The upcoming earnings report is the primary catalyst; investors should monitor for any changes to analyst estimates and closely watch whether the company meets or exceeds the projected ~4% EPS and ~5% revenue growth, as this will likely determine the stock's next directional move.